Lyell Immunopharma (LYEL) Income from Continuing Operations (2020 - 2026)
Lyell Immunopharma (LYEL) posted Income from Continuing Operations of 103216000.0 for Q1 2026, up 28.67% sequentially from 144693000.0 in Q4 2025, and up 19.91% YoY from 86074330.17 in Q1 2025.
Powered by 
Analysis
Lyell Immunopharma (LYEL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Income from Continuing Operations for 7 years, with the latest figure at 103216000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 19.91% year-over-year to 103216000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 465544000.0 (up 50.67% YoY) and the FY2025 annual result came in at 286543000.0, up 60.08% from the prior year.
- Income from Continuing Operations advanced to 103216000.0 in Q1 2026 per LYEL's latest filing, from 144693000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 13558000.0 in Q4 2022 and troughed at 561056000.0 in Q4 2024.
- A 5-year average of 149562764.71 and a median of 124408000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations jumped 92.31% in 2022, then sank 2163.17% in 2023.
- Over 5 years, Income from Continuing Operations stood at 13558000.0 in 2022, then tumbled by 2163.17% to 306841000.0 in 2023, then plunged by 82.85% to 561056000.0 in 2024, then surged by 74.21% to 144693000.0 in 2025, then climbed by 28.67% to 103216000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 103216000.0, 144693000.0, and 102168000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Lyell Immunopharma | 335.97 Mn | 335.97 Mn | - | -45.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -45.15 Mn |
| Mar 31, 2026 | -42.07 Mn |
| Dec 31, 2025 | -124.97 Mn |
| Sep 30, 2025 | -33.99 Mn |
| Jun 30, 2025 | -43.86 Mn |
| Mar 31, 2025 | -53.51 Mn |
| Dec 31, 2024 | -196.23 Mn |
| Sep 30, 2024 | -44.54 Mn |
| Jun 30, 2024 | -45.16 Mn |
| Mar 31, 2024 | -48.76 Mn |
| Dec 31, 2023 | -52.42 Mn |
| Sep 30, 2023 | -52.43 Mn |
| Jun 30, 2023 | -60.64 Mn |
| Mar 31, 2023 | -58.06 Mn |
| Dec 31, 2022 | 642,000.00 |
| Sep 30, 2022 | -64.19 Mn |
| Jun 30, 2022 | -39.01 Mn |
| Mar 31, 2022 | -73.55 Mn |
| Dec 31, 2021 | -50.26 Mn |
| Sep 30, 2021 | -48.89 Mn |